CCDC50 Gene Deafness Autosomal Dominant Type 44 Genetic Test
Test Components
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Ear Nose Throat Disorders
- Doctor: ENT Doctor
- Test Department: Genetics
Pre Test Information
Clinical History of Patient who is going for GJB2 Gene Deafness with keratopachydermia and constrictions of fingers and toes NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with GJB2 Gene Deafness with keratopachydermia and constrictions of fingers and toes NGS Genetic DNA Test gene GJB5.
Test Details
The CCDC50 gene is associated with a type of autosomal dominant deafness known as DFNA44 (Deafness, autosomal dominant type 44). Autosomal dominant means that an individual only needs to inherit one copy of the mutated gene from either parent to develop the condition.
NGS (Next-Generation Sequencing) is a genetic testing technique that allows for the simultaneous sequencing of multiple genes, including CCDC50, in a more efficient and cost-effective manner compared to traditional sequencing methods.
The NGS genetic test for CCDC50 gene deafness, autosomal dominant type 44 involves analyzing the DNA of an individual to identify any mutations or variations in the CCDC50 gene that may be responsible for their hearing loss. This test can help confirm a diagnosis, provide information about the inheritance pattern, and guide management and treatment options.
It is important to note that genetic testing for CCDC50 gene deafness, autosomal dominant type 44 is typically recommended for individuals with a family history of hearing loss or those who have early-onset or progressive hearing loss. The test is usually performed by a genetic counselor or a healthcare professional specialized in genetic testing and interpretation.
| Test Name | CCDC50 Gene Deafness autosomal dominant type 44 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Ear Nose Throat Disorders |
| Doctor | ENT Doctor |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for GJB2 Gene Deafness with keratopachydermia and constrictions of fingers and toes NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with GJB2 Gene Deafness with keratopachydermia and constrictions of fingers and toes NGS Genetic DNA Test gene GJB5 |
| Test Details | The CCDC50 gene is associated with a type of autosomal dominant deafness known as DFNA44 (Deafness, autosomal dominant type 44). Autosomal dominant means that an individual only needs to inherit one copy of the mutated gene from either parent to develop the condition. NGS (Next-Generation Sequencing) is a genetic testing technique that allows for the simultaneous sequencing of multiple genes, including CCDC50, in a more efficient and cost-effective manner compared to traditional sequencing methods. The NGS genetic test for CCDC50 gene deafness, autosomal dominant type 44 involves analyzing the DNA of an individual to identify any mutations or variations in the CCDC50 gene that may be responsible for their hearing loss. This test can help confirm a diagnosis, provide information about the inheritance pattern, and guide management and treatment options. It is important to note that genetic testing for CCDC50 gene deafness, autosomal dominant type 44 is typically recommended for individuals with a family history of hearing loss or those who have early-onset or progressive hearing loss. The test is usually performed by a genetic counselor or a healthcare professional specialized in genetic testing and interpretation. |
